title: Nebivolol prevents myocardial fibrosis and diastolic dysfunction in salt-loaded spontaneously hypertensive rats.
abstract: BACKGROUND
  We have demonstrated previously that a high-salt diet (HS) produces myocardial fibrosis, left ventricular (LV) dysfunction, and renal insufficiency in adult spontaneously hypertensive rats (SHR), and that blockade of the renin-angiotensin system prevented those adverse effects of HS.
  
  
  RESULTS
  Eight-week-old male SHR were divided into four groups: controls received regular rat chow (0.6 NaCl); the other three were given HS. The second group was given placebo; the third, nebivolol (2 × 10 mg/kg/day) orally; and, the fourth, the same dose of nebivolol by osmotic minipump. Rats received respective treatments for 8 weeks. The data demonstrated that the HS induced increased cardiac mass (2.85 ± 0.05 vs. 5.36 ± 0.22 mg/g; P < .05 in control and HS groups, respectively); LV fibrosis as indicated by higher hydroxyproline concentration; further increase in arterial pressure (161 ± 7 vs. 184 ± 8 mm Hg; P < .05); myocardial ischemia; and LV diastolic dysfunction. Nebivolol ameliorated the adverse cardiac effects of HS, demonstrated by decreased LV mass and fibrosis and improved coronary hemodynamics and LV function.
  
  
  CONCLUSIONS
  The effects of nebivolol were independent of arterial pressure. The results of this study provide important laboratory data that support a rationale for nebivolol in the treatment of patients with hypertension having diastolic dysfunction with preserved ejection fraction.
authors.affiliation: Hypertension Research Laboratory, Institute of Translational Research, Ochsner Clinic Foundation, New Orleans, LA 70121, USA. dsusic@ochsner.org
authors.forename: Dinko
authors.initials: D
authors.lastname: Susic
authors.forename: Hassan
authors.initials: H
authors.lastname: Fares
authors.forename: Edward D
authors.initials: ED
authors.lastname: Frohlich
mesh_terms: D000284:Administration, Oral; D058671:Adrenergic beta-1 Receptor Antagonists / Q000008:administration & dosage / Q000493:pharmacokinetics; D000818:Animals; D001578:Benzopyrans / Q000008:administration & dosage / Q000493:pharmacokinetics; D001682:Biological Availability; D001794:Blood Pressure / Q000187:drug effects*; D002316:Cardiotonic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics; D004983:Ethanolamines / Q000008:administration & dosage / Q000493:pharmacokinetics; D005355:Fibrosis / Q000139:chemically induced / Q000378:metabolism / Q000517:prevention & control; D006439:Hemodynamics; D006801:Humans; D006909:Hydroxyproline / Q000378:metabolism; D007260:Infusion Pumps; D007267:Injections / Q000379:methods; D023421:Models, Animal; D009200:Myocardial Contraction / Q000187:drug effects*; D017202:Myocardial Ischemia / Q000139:chemically induced / Q000517:prevention & control; D009206:Myocardium / Q000378:metabolism / Q000473:pathology; D000068577:Nebivolol; D051381:Rats; D011918:Rats, Inbred SHR; D017673:Sodium Chloride, Dietary / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D018487:Ventricular Dysfunction, Left / Q000139:chemically induced / Q000378:metabolism / Q000517:prevention & control
chemical_list: D058671:Adrenergic beta-1 Receptor Antagonists; D001578:Benzopyrans; D002316:Cardiotonic Agents; D004983:Ethanolamines; D017673:Sodium Chloride, Dietary; D000068577:Nebivolol; D006909:Hydroxyproline